Storia in 2 fonti

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.

Raccontata da

cnbc.com

forbes.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo6 mesi fa

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.

originale

forbes.com6 mesi fa

Pfizer To Pay $150 Million Upfront To Fosun Pharma In New China Move

Partnership follows tie-up with China's 3SBio earlier this year

Leggi questa versione → originale

Timeline cronologica

martedì 9 dicembre 2025·cnbc.com
Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill
The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.
mercoledì 10 dicembre 2025·forbes.com
Pfizer To Pay $150 Million Upfront To Fosun Pharma In New China Move
Partnership follows tie-up with China's 3SBio earlier this year